To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

NCT07116473 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis in Transthyretin (TTR)
Amyloidosis, Familial
Amyloid Cardiomyopathy
Amyloid Cardiomyopathy, Transthyretin-Related
Amyloidogenic Transthyretin (ATTR) Amyloidosis
Heart Disease
Cardiomyopathies
Amyloidosis, Hereditary, Transthyretin-Related
Polyneuropathies
Amyloidosis

Interventions

DRUG: Acoramidis (AG10)

Sponsor

Eidos Therapeutics, a BridgeBio company